source
- Osivax licenses GC Biopharma seasonal flu vaccine to develop combined OVX836-GC FLU shotOsivax has secured a non-exclusive license from GC Biopharma for its seasonal influenza vaccine, GC FLU, to pair with Osivax’s mid-phase candidate OVX836. OVX836 targets the conserved nucleoprotei…
- Proposed Biotech Investment National Security Act may protect US firms but contains loophole aiding Chinese competitionA bipartisan bill called the Biotech Investment National Security Act (BINSA) has been introduced in Congress to expand federal oversight of biotechnology activities, from drug development to biolo…